Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer

THURSDAY, Nov. 14, 2019 -- The checkpoint inhibitor pembrolizumab prolongs survival in patients with certain head and neck cancers, according to a phase 3 study published online Oct. 31 in The Lancet. Barbara Burtness, M.D., from the Yale University...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news